Calithera Biosciences Stock Net Asset
| CALADelisted Stock | USD 0.05 0.00 0.00% |
Calithera Biosciences fundamentals help investors to digest information that contributes to Calithera Biosciences' financial success or failures. It also enables traders to predict the movement of Calithera Pink Sheet. The fundamental analysis module provides a way to measure Calithera Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Calithera Biosciences pink sheet.
Calithera |
Calithera Biosciences Company Net Asset Analysis
Calithera Biosciences' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Calithera Biosciences Net Asset | 28.68 M |
Most of Calithera Biosciences' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calithera Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Calithera Biosciences has a Net Asset of 28.68 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Calithera Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calithera Biosciences' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Calithera Biosciences could also be used in its relative valuation, which is a method of valuing Calithera Biosciences by comparing valuation metrics of similar companies.Calithera Biosciences is currently under evaluation in net asset category among its peers.
Calithera Fundamentals
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | (1.1 M) | ||||
| Shares Outstanding | 4.87 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 26.76 % | ||||
| Number Of Shares Shorted | 417.28 K | ||||
| Price To Earning | (14.08) X | ||||
| Price To Book | 1.86 X | ||||
| Price To Sales | 1.71 X | ||||
| Gross Profit | (42.7 M) | ||||
| EBITDA | (43.77 M) | ||||
| Net Income | (39.65 M) | ||||
| Cash And Equivalents | 41.79 M | ||||
| Cash Per Share | 8.59 X | ||||
| Total Debt | 1.67 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.82 X | ||||
| Book Value Per Share | (0.40) X | ||||
| Cash Flow From Operations | (43.61 M) | ||||
| Short Ratio | 0.78 X | ||||
| Earnings Per Share | (1.59) X | ||||
| Price To Earnings To Growth | (0.29) X | ||||
| Target Price | 5.0 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 341.07 K | ||||
| Total Asset | 28.68 M | ||||
| Retained Earnings | (512.62 M) | ||||
| Working Capital | 19.23 M | ||||
| Current Asset | 72.5 M | ||||
| Current Liabilities | 3.83 M | ||||
| Z Score | -29.14 | ||||
| Net Asset | 28.68 M |
About Calithera Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calithera Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calithera Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calithera Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Calithera Pink Sheet
If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |